Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

NCT05075928 | Unknown

• 1 other identifier: 7861
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.

Conditions

SARS-COV-2

Keywords

SARS-COV-2; Covid-19; Antiphospholipid syndrome (APS); autoimmune disease; antiphospholipid antibodies (aPL); thrombosis

Outcome Measures

Primary Outcomes (1)

• Retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant

  Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment

You may qualify if:

• Adult patient (≥18 years old)
• Patient taken care of in the SMO pole or the NHC surgical resuscitation service or hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020
• Patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment
• or Patient infected with Covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in TCA revealing the presence of LA
• Subject having given his agreement for the reuse of his data for the purposes of this research

You may not qualify if:

• Subject having expressed opposition to participating in the study
• Subject under guardianship or guardianship
• Subject under safeguard of justice

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

COVID-19; Antiphospholipid Syndrome; Autoimmune Diseases; Thrombosis

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Immune System Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Anne-Sophie Korganow, MD, PhD

  Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anne-Sophie Korganow, MD, PhD

CONTACT

33 3 69 55 05 21; Anne-sophie.Korganow@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 6, 2021
• First Posted: October 13, 2021
• Study Start: June 1, 2020
• Primary Completion: November 1, 2021
• Study Completion: November 1, 2021
• Last Updated: December 1, 2021

Record last verified: 2021-10

Locations

FR (1)